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Avoiding exploitation in multinational covid-19 vaccine trials
Low and middle income countries must benefit, not just participate
Alexander A Iyer, Joseph Millum, Christine Grady, David Wendler
Highly efficacious vaccines for covid-19 arenowbeing
distributed in high income countries. At the same
time, multinational covid-19 vaccine trials
continue—andnew trials are beingplanned—around
the world.1
People in high income countries who have access to
efficacious vaccines may be unwilling to enrol or
remain in trials testingunprovedvaccines—especially
trials with a placebo arm. As a result, ongoing and
futuremultinational covid-19 vaccine trialsmayhave
to rely on participants from low and middle income
countries (LMICs), where access to vaccines remains
limited. It is critical to ensure that trials do not exploit
these individuals and countries.
The fact that most people in LMICs lack access to
covid-19 vaccines results from unjust wealth
differences between countries, and fromhigh income
countries purchasing a disproportionate share of
global vaccine supplies.2 However, responding to
this injustice by declining to enrol people from LMICs
would be problematic. First, it would deny them the
potential benefits of receiving an investigational
vaccine. Second, it could impede the development
of additional covid-19 vaccines, including those with
high value for LMICs in particular. For example,
vaccines that do not require ultracold storage could
contribute substantially to tackling the pandemic in
countries where some existing vaccines cannot be
distributed.3
A better approach is to design multinational vaccine
trials to avoid worsening existing injustices and
mitigate themwhenpossible.Most importantly, these
trials should not exploit individuals, communities,
or countries that lack access to covid-19 vaccines.
Recent reports from LMICs raise concerns in this
regard,4 highlighting a need for clear guidance.
Exploitation occurs when trial participants or host
communities do not benefit fairly given the burdens
and risks they face, and the benefits others receive
from their participation. A trial that enrolled
participants largely from LMICs but made any
resulting vaccine available only in high income
countries, would be exploitative. To avoid
exploitation, multinational covid-19 vaccine trials
should satisfy several requirements in addition to
those that apply to all clinical trials (such as informed
consent and fair participant selection).5 Funders,
regulators, and review committees should ensure
that sufficient oversight and accountability
mechanisms are in place to see that these
requirements are satisfied in practice.
First, trials should be responsive to host countries’
health needs.6 Evaluating a vaccine that would be
cheaper, easier to distribute, ormore effective against
local SARS-CoV-2 variants could satisfy this
condition. In addition, while global vaccine scarcity
persists, evaluating any vaccine that could be used
in host countries would be locally responsive.
Second, vaccines that are found to be safe and
effective should bemade available in host countries.6
When most or all of a trial’s participants come from
LMICs, these countries should receive
correspondingly higher priority for any resulting
vaccine. If a trial does not yield an effective vaccine,
host countries should benefit in other ways, such as
through improvements to health infrastructure.
Third, trials should not make participants
substantiallyworseoff. To this end, consentprocesses
should warn participants not to assume they will
receive an effective vaccine, and to avoid risky
behaviour throughout the trial. Participants should
receive high quality healthcare if they develop
covid-19, and free treatment for any research related
harms. When trial participation ends, individuals
should be informed whether they received the
covid-19 vaccine or a control intervention, and
counselled about future options, including any risks
associated with receiving a different vaccine.
Fourth, trials should be planned and conducted in
partnership with host countries. Host countries
should help determine the acceptability of proposed
trials, the type and magnitude of benefits they will
receive, and the steps needed to ensure a trial does
not undermine local health systems.6
Fifth, investigators, sponsors, and funders should be
transparent and explain to the public why testing
additional vaccines is valuable after effective vaccines
have been identified.
Even when the above conditions are satisfied,
multinational covid-19 vaccine trials may be
perceived as unfair if most participants come from
LMICs. Investigators, sponsors, and funders should
consider ways to balance enrolment by increasing
recruitment and retentionofparticipants fromoutside
LMICs.
For example, investigators might encourage trial
participants who become eligible for a covid-19
vaccine outside of research to defer receiving it and
continue to participate in the trial. This can be
appropriate for people who would not face excessive
risks as a result, such as those at low risk for severe
covid-19. A second, and potentially supplementary
approach, would be to guarantee that, once the trial
ends, all participants will be offered an effective
vaccine. A third option would be to stipulate that all
participants who become eligible for vaccination
outside of research will be unblinded and, if in the
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placebo arm, offered the investigational vaccine with continued
follow-up.
Even as safe and effective covid-19 vaccines are deployed, there
remains substantial value in developing additional vaccines. With
careful steps to avoid exploiting people in LMICs, multinational
trials can offer an ethical way to accomplish this goal.
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